HomeStock SectorsBioTechShould You Hold Akebia...

Should You Hold Akebia Therapeutics Inc (AKBA) in Biotechnology Industry?

News Home

Tuesday, February 07, 2023 11:38 AM | InvestorsObserver Analysts

Mentioned in this article

The 72 rating InvestorsObserver gives to Akebia Therapeutics Inc (AKBA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 85 percent of stocks in the Biotechnology industry, AKBA’s 72 overall rating means the stock scores better than 72 percent of all stocks.

Overall Score - 72
AKBA has an Overall Score of 72. Find out what this means to you and get the rest of the rankings on AKBA!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 72 would rank higher than 72 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What’s Happening With Akebia Therapeutics Inc Stock Today?

Akebia Therapeutics Inc (AKBA) stock is trading at $1.09 as of 11:37 AM on Tuesday, Feb 7, a rise of $0.01, or 1.4% from the previous closing price of $1.07. The stock has traded between $0.99 and $1.11 so far today. Volume today is less active than usual. So far 1,229,845 shares have traded compared to average volume of 2,093,358 shares.

Click Here to get the full Stock Report for Akebia Therapeutics Inc stock.

You May Also Like

Most Popular

More from Author

Oil Prices Expected to Stay Under $70

Analysts widely expect oil prices to remain below $70 per barrel...

Markets Await Trade Deals as Trump Makes New Tariff Threats

Dollar edges higher, gold slips despite confusion and renewed trade tensions Trump...

Gold Prices Under Pressure as Tariff Talks Offset Geopolitical Risks

Tariff Negotiations Weigh Down on Gold Gold () rose slightly on Friday...

Oil Price Retreats but Bullish Technicals Suggest Upside Ahead

The NA session kicks off quietly, with subdued volumes as American...

Read Now

Oil Prices Expected to Stay Under $70

Analysts widely expect oil prices to remain below $70 per barrel for the remainder of 2025, primarily due to global oversupply and ongoing uncertainties regarding demand. Despite heightened geopolitical tensions in the Middle East, these factors are not anticipated to significantly drive up oil prices unless direct supply...

Markets Await Trade Deals as Trump Makes New Tariff Threats

Dollar edges higher, gold slips despite confusion and renewed trade tensions Trump delays tariff deadline to August 1, says trade deals are close Wall Street hits record after Congress passes Big Beautiful Bill Oil recovers from lows after OPEC+ hikes output more than expected New Threats and ExtensionsThe dreaded July 9...

Gold Prices Under Pressure as Tariff Talks Offset Geopolitical Risks

Tariff Negotiations Weigh Down on Gold Gold () rose slightly on Friday as markets adjusted amid evolving trade headlines. However, it pulled back during the day as traders monitored negotiations with key U.S. trade partners, many aiming to finalise deals or secure more time ahead of approaching deadlines....

Oil Price Retreats but Bullish Technicals Suggest Upside Ahead

The NA session kicks off quietly, with subdued volumes as American traders take the day off, giving markets a breather after the upside surprise in the last week and fresh diplomatic updates from the US. From a price action perspective, has been consolidating in a narrow...

Stocks Week Ahead: Can Small-Business Optimism, Inflation Clues Keep Bulls Alive?

There’s not much on this week’s economic calendar. The only big event was supposed to occur on Wednesday, July 9. That would have been 90 days after President Donald Trump postponed his April 2 reciprocal tariffs on America’s trading partners on April 9 for 90 days. Today,...

June Payrolls Jump, but Other Growth Indicators Paint a Sluggish Picture

June beats consensus on the back of education and health services employment, while private NFP surprises downside. With S&P Global monthly flat over the last six months through May, many key indicators followed by the NBER  Business Cycle Dating Committee (BCDC) are flat or falling...

Fed Gets Breathing Room as Labor Market Holds Firm

The monthly jobs report hit today (unusually, on a Thursday, due to the real and perfectly sensible holiday tomorrow blocking the typical Friday release) and the reaction was immediate. All the equity futures remain strong, but paradoxically, it can sometimes be a spike to the upside that...

How California’s Housing Reforms Could Reshape US Cities Over the Next Decade

Things are moving fast these days. Texans for Reasonable Solutions, among others, has helped push through a number of housing reforms in Texas. Maine has passed a couple of bills that should allow more step-change urban development, as I put it in the “Market Segmentation” post. And California has suddenly...

Week Ahead – RBA, RBNZ Decisions and Fed Minutes Eyed as Trade Deals Awaited

July 9 tariff deadline looms as trade deals remain elusive Fed minutes to be watched after positive jobs report RBA expected to cut but RBNZ to likely stay on hold OPEC+ to probably raise output again UK GDP, Canadian employment and Chinese CPI data also on tap The Race to the Finish...

The Fiscal Treadmill Is Speeding Up and Washington Keeps Jogging

As of 1980, the rolling 10-year and 20-year real GDP growth rates stood at 3.2% per annum and 3.5% per annum, respectively. Owing to a slight boost from the good parts of Reaganomics—sweeping deregulation, tax rate cuts, and sound money, which were partially offset by the long-term ills...

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera's Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy SolutionsDistinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence Steinman have joined Immuthera's Scientific Advisory Board.Immuthera will continue expanding its Scientific Advisory Board over the coming months to build a truly world-class team.In collaboration...

Risk Assets Extend Gains but Low Volumes Could Skew Monday Open

Yesterday’s market action was driven by consecutive upside surprises in US (147K vs 110K exp) and data (50.8 vs 50.5 exp), fueling another wave of positive sentiment and pushing US equities into yet another frenzied rally. The reaction to the data was progressive but consistent, taking...